Table 3. Prognostic significance for progression-free survival of the immunohistochemistry profile and other parameters by Cox univariate and multivariate analyses.

		Univariate			Multivariate
		HR	95%CI	p	HR	95%CI	p
No. of	1–2 organs
metastases	≥3 organs	1.12	0.66–1.90	0.67	0.92	0.43–1.99	0.84
Liver	No
metastasis	Yes	1.30	0.55–3.04	0.55	1.36	0.51–3.62	0.54
Bone	No
metastasis	Yes	1.80	0.94–3.45	0.08	1.73	0.77–3.89	0.19
Performance	0–1
score	2	2.86	1.71–4.77	<0.001	3.32	1.81–6.08	<0.001
Gender	Female
	Male	0.70	0.43–1.14	0.15	0.33	0.17–0.66	0.002
Age	≥65
	<65	0.62	0.37–1.10	0.08	0.57	0.32–1.03	0.06
Profile	Liver/Kidney
	Prostate	0.30	0.10–0.93	0.04	0.38	0.09–1.52	0.17
	Digestive	0.52	0.19–1.42	0.20	0.44	0.13–1.46	0.18
	Breast	0.78	0.22–2.77	0.70	0.48	0.13–1.82	0.28
	Urothelial	1.58	0.31–7.98	0.58	0.46	0.08–2.58	0.38
	Lung	0.27	0.10–0.72	0.009	0.31	0.10–1.00	0.05
	Gynecological	0.18	0.06–0.59	0.004	0.08	0.02–0.30	<0.001
	Not identified	0.44	0.16–1.20	0.11	0.40	0.14–1.21	0.11

HR, hazard ratio; CI, confidence interval; PS, performance status.